Study Shows that Cannabis Extracts May Help in the Prevention of Certain CV19 Symptoms

FN Media Group Presents Microsmallcap.com Market Commentary

 

New York, NY – March 9, 2021 – After facing scrutiny last spring, new research suggests that using cannabis to help treat and prevent COVID-19 isn’t so far-fetched after all. Researchers at the University of Lethbridge are advancing to clinical trials after study results revealed that certain cannabis strains might help prevent COVID-19 patients from experiencing acute respiratory distress (ARDS). At the same time, Michigan State University professor of pharmacology and toxicology Norbert Kaminski is working with GB Sciences, a biopharmaceutical company, to develop a drug that prevents the lung inflammation that some experience after contracting COVID-19 that can lead to trouble breathing and death. The positive test results from these various studies bode well for cannabis companies that have a stake in the edibles and extracts sector, such as industry giants Canopy Growth (NASDAQ:CGC) (TSX:WEED), Tilray, Inc. (NASDAQ:TLRY), Aphria (NASDAQ:APHA) (TSX:APHA), HEXO Corp. (NYSE:HEXO) (TSX:HEXO), and plant-based extraction company Pure Extracts Technologies (CSE:PULL) (OTCPK:PRXTF).

 

Pure Extract Technologies, which is focused on producing the purest and highest quality cannabis oil at its all-new, state-of-the-art EU-GMP certified processing facility, has the ability to not only produce its own line of high-quality cannabis oil products but to distribute its concentrates through existing distribution channels.

 

In January, Pure Extracts Technologies took advantage of low biomass prices by entering into a substantial purchase agreement in order to scale-up production of both its THC and CBD extracts. The company agreed to purchase 220 kilograms of high-potency cannabis dried flower from a large Canadian licensed producer and 1,000 kgs of high-potency CBD biomass from a top Western Canadian cultivator.

 

Less than a month later, Pure Extracts Technologies announced its first commercial sale of its 85% pure CBD distillate, which is ideally suited for cannabis 2.0 products like edibles, vape pens, and cannabis-infused beverages.

 

Pure Extracts has also been working on developing its own line of products and recently submitted a Notice of New Cannabis Product application to Health Canada and over 20 SKUs for its THC and CBD vapes and three different formulations of gummies. The company has also signed an agreement with fully integrated medical cannabis company Canada House Wellness Group, which will distribute its line of concentrate products through its established provincial distribution channels.

 

While Pure Extracts Technologies is targeting the recreational adult-use cannabis market with its 34 proprietary formulations of ‘Pure Pulls’ full spectrum oil vapes and its new line of ‘Pure Chews’ edible gummies, the high-purity oil could be a good candidate for medical cannabis developments, including cannabis mouthwash that could potentially help in the fight against COVID-19.

 

Researchers Develop Medical Cannabis Oral Rinse for Potential Treatment of COVID-19

 

In April 2020, pandemic panic sparked several sensational claims that cannabis could cure COVID-19, which were quickly chalked up to hearsay. However, more and more research is pointing to the plant’s potential role in the fight against viral outbreaks like the coronavirus.

 

For the last four years, University of Lethbridge biology professors Igor and Olga Kovalchuk have been working with cannabis strains around the world to create new hybrids that have certain therapeutic properties. In February 2021, the pair revealed that the results from their research demonstrate that certain high-CBD cannabis sativas have the potential to become a useful and safe addition to COVID-19 treatment and could be developed into preventative treatments in the form of mouthwash, inhalers, or throat gargles.

 

While the professors still need to conduct animal and human studies to test the efficacy of the strains, the initial results are very promising. If cannabis mouth rinses prove to be a success, it could bode well for companies already involved in the infused beverages space.

 

Canadian pharmaceutical and cannabis company Tilray, Inc. (NASDAQ:TLRY) entered the cannabis beverages space in 2019 through a joint venture with the world’s largest brewer and Budweiser’s parent company Anheuser-Busch. In December 2019, the JV announced that it would be launching CBD-infused teas in Canada, with non-alcoholic sparkling drinks to follow in 2020. In December 2019, their company Fluent Beverages launched its first 98% pure CBD-infused beverage.

 

Tilray will likely increase its cannabis beverage offerings following the announcement of an all-stock merger with Aphria (NASDAQ:APHA) (TSX:APHA). The $4 billion deal will not only make the pair the world’s largest cannabis company by revenue, but it will also boost their cannabis beverage-making capabilities thanks to Aphria’s recent purchase of Sweetwater Brewing.

 

Canopy Growth (NASDAQ:CGC) (TSX:WEED) entered the cannabis beverage space in 2020 when it received backing from US alcoholic beverage giant Constellation Brands. The company launched its first THC-infused drink to the Canadian market in March 2020 and has continued to roll out its North American strategy. In November, Canopy expanded its beverage portfolio with a CBD-infused beverage line, which is now being launched in the US.

 

Molson Coors Canada and Quebec-based cannabis producer HEXO Corp. (NYSE:HEXO) (TSX:HEXO) announced a similar partnership in 2019 and finally launched their cannabis-infused beverage to the market in August 2020 under the brand name Truss Beverage. In January 2021, Truss announced the US launch of Verywell, a new line of non-alcoholic sparkling CBD beverages, which will be available in Colorado.

 

It’s unclear whether or not cannabis beverage producers will have the opportunity to develop infused drinks with therapeutic properties, but with growing research and development surrounding the potential benefits of cannabis, it could very well become a reality.

 

Plant-based extraction company Pure Extracts Technologies could also benefit the medical cannabis market with its high-purity extraction methods. In the meantime, the company is focused on building a presence in the cannabis edibles market.

 

For more information on Pure Extracts Technologies (CSE:PULL) (OTC:PRXTF), please visit this link.

 

DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above.  References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

 

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Pure Extracts.

 

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

Media Contact:
FN Media Group, LLC
info@financialnews.com
+1(561)325-8757

Source: Microsmallcap.com

Sign Up & Get FREE News Alerts From FNM Today!